<?xml version="1.0" encoding="UTF-8"?>
<compound>
  <id type="integer">2857</id>
  <title>T3D2815</title>
  <common-name>Dextromethorphan</common-name>
  <description>Dextromethorphan is an antitussive drug that is found in many over-the-counter cold and cough preparations, usually in the form of dextromethorphan hydrobromide. Dextromethorphan is a salt of the methyl ether dextrorotatory isomer of levorphanol, a narcotic analgesic. Dextromethorphan occurs as white crystals, is sparingly soluble in water, and freely soluble in alcohol. The drug is dextrorotatory in water (at 20 degrees Celsius, Sodium D-line) with a specific rotation of +27.6 degrees. Following oral administration, dextromethorphan is rapidly absorbed from the gastrointestinal tract, where it enters the bloodstream and crosses the blood-brain barrier. Dextromethorphan shows high affinity binding to several regions of the brain, including the medullary cough center. The first-pass through the hepatic portal vein results in some of the drug being metabolized into an active metabolite of dextromethorphan, dextrorphan, the 3-hydroxy derivative of dextromethorphan. The therapeutic activity of dextromethorphan is believed to be caused by both the drug and this metabolite. Dextromethorphan is predominantly metabolized by the liver, by various hepatic enzymes. Through various pathways, the drug undergoes (O-demethylation (which produces dextrorphan), N-demethylation, and partial conjugation with glucuronic acid and sulfate ions. The inactive metabolite (+)-3-hydroxy-N-methylmorphinan is formed as a product of DXM metabolism by these pathways. One well known metabolic catalyst involved is a specific cytochrome P450 enzyme known as 2D6, or CYP2D6. A significant portion of the population has a functional deficiency in this enzyme (and are known as poor CYP2D6 metabolizers). As CYP2D6 is the primary metabolic pathway in the inactivation of dextromethorphan, the duration of action and effects of dextromethorphan are significantly increased in such poor metabolizers. Deaths and hospitalizations have been reported in recreational use by poor CYP2D6 metabolizers. -- Wikipedia. This compound is an NMDA receptor antagonist (receptors, N-methyl-D-aspartate) and acts as a non-competitive channel blocker. It is also used to study the involvement of glutamate receptors in neurotoxicity. [PubChem] It is also the d-isomer of the codeine analog of levorphanol. Dextromethorphan shows high affinity binding to several regions of the brain, including the medullary cough center. This compound is an NMDA receptor antagonist (receptors, N-methyl-D-aspartate) and acts as a non-competitive channel blocker. It is one of the widely used antitussives, and is also used to study the involvement of glutamate receptors in neurotoxicity.</description>
  <cas>125-71-3</cas>
  <pubchem-id>5362449</pubchem-id>
  <chemical-formula>C18H25NO</chemical-formula>
  <weight>271.193610</weight>
  <appearance>White powder.</appearance>
  <melting-point>122-124°C</melting-point>
  <boiling-point nil="true"/>
  <density nil="true"/>
  <solubility>74.7 mg/L</solubility>
  <specific-gravity nil="true"/>
  <flash-point nil="true"/>
  <vapour-pressure nil="true"/>
  <route-of-exposure>Oral, rapidly absorbed from the gastrointestinal tract.</route-of-exposure>
  <target nil="true"/>
  <mechanism-of-toxicity>Dextromethorphan is an opioid-like drug that binds to and acts as antagonist to the NMDA glutamatergic receptor, it is an agonist to the opioid sigma 1 and sigma 2 receptors, it is also an alpha3/beta4 nicotinic receptor antagonist and targets the serotonin reuptake pump. Dextromethorphan is rapidly absorbed from the gastrointestinal tract, where it enters the bloodstream and crosses the blood-brain barrier. The first-pass through the hepatic portal vein results in some of the drug being metabolized into an active metabolite of dextromethorphan, dextrorphan, the 3-hydroxy derivative of dextromethorphan.</mechanism-of-toxicity>
  <metabolism>Hepatic. Rapidly and extensively metabolized to dextrorphan (active metabolite). One well known metabolic catalyst involved is a specific cytochrome P450 enzyme known as 2D6, or CYP2D6.Half Life: 3-6 hours</metabolism>
  <toxicity>LD50: 165 mg/kg (mice) (L1858)
LD50: 350 mg/kg (rat) (L1858)
</toxicity>
  <lethaldose nil="true"/>
  <carcinogenicity>No indication of carcinogenicity to humans (not listed by IARC).</carcinogenicity>
  <use-source>The primary use of dextromethorphan is as a cough suppressant, for the temporary relief of cough caused by minor throat and bronchial irritation (as commonly accompanies the common cold), as well as those resulting from inhaled irritants. In addition, a combination of dextromethorphan and quinidine has been shown to alleviate symptoms of easy laughing and crying (pseudobulbar affect) in patients with amyotrophic lateral sclerosis and multiple sclerosis.</use-source>
  <min-risk-level nil="true"/>
  <health-effects>Hypertension, shallow respiration. Dextromethorphan can cause other gastrointestinal disturbances. [Wikipedia]</health-effects>
  <symptoms>symptoms include vomitting, drowiness, diarrhea, urinary retention, fever, and sweating. [Wikipedia]</symptoms>
  <treatment nil="true"/>
  <created-at type="dateTime">2009-07-21T20:27:05Z</created-at>
  <updated-at type="dateTime">2014-12-24T20:25:51Z</updated-at>
  <interacting-proteins nil="true"/>
  <wikipedia>Dextromethorphan</wikipedia>
  <uniprot-id></uniprot-id>
  <kegg-compound-id>C06947</kegg-compound-id>
  <omim-id></omim-id>
  <chebi-id>4470</chebi-id>
  <biocyc-id></biocyc-id>
  <ctd-id nil="true"/>
  <stitch-id>Dextromethorphan</stitch-id>
  <drugbank-id>DB00514</drugbank-id>
  <pdb-id></pdb-id>
  <actor-id nil="true"/>
  <organism nil="true"/>
  <export type="boolean">true</export>
  <metabolizing-proteins nil="true"/>
  <transporting-proteins nil="true"/>
  <moldb-smiles>[H][C@@]12CC3=C(C=C(OC)C=C3)[C@]3(CCCC[C@@]13[H])CCN2C</moldb-smiles>
  <moldb-formula>C18H25NO</moldb-formula>
  <moldb-inchi>InChI=1/C18H25NO/c1-19-10-9-18-8-4-3-5-15(18)17(19)11-13-6-7-14(20-2)12-16(13)18/h6-7,12,15,17H,3-5,8-11H2,1-2H3/t15-,17+,18+/s2</moldb-inchi>
  <moldb-inchikey>InChIKey=MKXZASYAUGDDCJ-HPAQEFICNA-N</moldb-inchikey>
  <moldb-average-mass type="decimal">271.3972</moldb-average-mass>
  <moldb-mono-mass type="decimal">271.193614427</moldb-mono-mass>
  <origin>Exogenous</origin>
  <state>Solid</state>
  <logp>3.6</logp>
  <hmdb-id>HMDB01920</hmdb-id>
  <chembl-id>CHEMBL52440</chembl-id>
  <chemspider-id>4642423</chemspider-id>
  <structure-image-file-name nil="true"/>
  <structure-image-content-type nil="true"/>
  <structure-image-file-size type="integer" nil="true"/>
  <structure-image-updated-at type="dateTime" nil="true"/>
  <biodb-id nil="true"/>
  <synthesis-reference>&lt;p&gt;Mahendra R. Patel, &amp;#8220;Sustained Release Suspension Preparation For Dextromethorphan.&amp;#8221; U.S. Patent US20130115253, issued May 09, 2013.&lt;/p&gt;</synthesis-reference>
  <structure-image-caption nil="true"/>
</compound>
